| Summary: | Aim: This study assessed the cost–utility of mogamulizumab, a novel monoclonal antibody, versus
established clinical management (ECM) in UK patients in previously treated advanced mycosis fungoides
(MF)/S ´ ezary syndrome (SS). Materials & methods: Lifetime partitioned survival model based on overall
survival, next treatment-free survival and the use of allogeneic stem cell transplant was developed. Inputs
were from the pivotal MAVORIC trial, real-world evidence and published literature. Extensive sensitivity
analyses were conducted. Results: Discounted incremental quality-adjusted life years (QALYs), costs and
incremental cost–effectiveness ratio were 3.08, £86,998 and £28,233. Results were most sensitive to the
survival extrapolations, utilities and costs after loss of disease control. Conclusion: Mogamulizumab is a
cost-effective alternative to ECM in UK patients with previously treated advanced MF/SS.
|
|---|